A
Arnaud Mejean
Researcher at Paris Descartes University
Publications - 307
Citations - 10605
Arnaud Mejean is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Renal cell carcinoma & Nephrectomy. The author has an hindex of 49, co-authored 269 publications receiving 9086 citations. Previous affiliations of Arnaud Mejean include Necker-Enfants Malades Hospital.
Papers
More filters
Journal ArticleDOI
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
Alexandre Loupy,Carmen Lefaucheur,Dewi Vernerey,Christof Prugger,Jean-Paul Duong Van Huyen,Nuala Mooney,Caroline Suberbielle,Véronique Frémeaux-Bacchi,Arnaud Mejean,François Desgrandchamps,Dany Anglicheau,Dominique Nochy,Dominique Charron,Jean-Philippe Empana,Michel Delahousse,Christophe Legendre,Denis Glotz,Gary S. Hill,Adriana Zeevi,Xavier Jouven +19 more
TL;DR: Assessment of the complement-binding capacity of donor-specific anti-HLA antibodies appears to be useful in identifying patients at high risk for kidney-allograft loss.
Journal ArticleDOI
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Arnaud Mejean,Alain Ravaud,Simon Thezenas,Sandra Colas,Jean-Baptiste Beauval,Karim Bensalah,Lionnel Geoffrois,Antoine Thiery-Vuillemin,Luc Cormier,Herve Lang,Laurent Guy,G. Gravis,Frederic Rolland,Claude Linassier,Eric Lechevallier,Christian Beisland,Michael Aitchison,Stéphane Oudard,Jean-Jacques Patard,Christine Theodore,Christine Chevreau,B. Laguerre,Jacques Hubert,Marine Gross-Goupil,Jean-Christophe Bernhard,Laurence Albiges,Marc-Olivier Timsit,Thierry Lebret,Bernard Escudier +28 more
TL;DR: Sunitinib alone was not inferior to nephrectomy followed by sunit inib in patients with metastatic renal‐cell carcinoma who were classified as having intermediate‐risk or poor‐risk disease.
Journal ArticleDOI
Multi-institutional validation of a new renal cancer-specific survival nomogram.
Pierre I. Karakiewicz,Alberto Briganti,Felix K.-H. Chun,Quoc-Dien Trinh,Paul Perrotte,Vincenzo Ficarra,Luca Cindolo,Alexandre de la Taille,Jacques Tostain,Peter F.A. Mulders,Laurent Salomon,Richard Zigeuner,Tommaso Prayer-Galetti,Denis Chautard,Antoine Valeri,Eric Lechevallier,Jean Luc Descotes,Herve Lang,Arnaud Mejean,Jean Jacques Patard +19 more
TL;DR: The new nomogram is more contemporary, provides predictions that reach further in time and, compared with its alternative, which predicts at 2 and 5 years, generates 3.1% and 2.8% more accurate predictions, respectively.
Journal ArticleDOI
Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts.
TL;DR: New objectives include targeted agents that could further widen USCA applications to specific delivery of active drugs such as anticoagulants or cytotoxic compounds.
Journal ArticleDOI
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Nicolas A. Giraldo,Nicolas A. Giraldo,Nicolas A. Giraldo,Etienne Becht,Etienne Becht,Etienne Becht,Franck Pagès,Georgios P Skliris,Virginie Verkarre,Yann Vano,Arnaud Mejean,Nicolas Saint-Aubert,Laetitia Lacroix,Laetitia Lacroix,Laetitia Lacroix,Ivo Natario,Ivo Natario,Ivo Natario,Audrey Lupo,Marco Alifano,Diane Damotte,Aurélie Cazes,Frédéric Triebel,Gordon J. Freeman,Marie-Caroline Dieu-Nosjean,Marie-Caroline Dieu-Nosjean,Marie-Caroline Dieu-Nosjean,Stéphane Oudard,Wolf H. Fridman,Catherine Sautès-Fridman +29 more
TL;DR: The expression of the immune checkpoints and the localization of DC in the tumor microenvironment modulate the clinical impact of CD8+ T cells in ccRCC.